Please use this identifier to cite or link to this item:
|Title:||Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics?|
|Authors:||Bosanac, Peter;Norman, Trevor R;Burrows, Graham D;Beumont, Peter|
|Affiliation:||Austin Health and Department of Psychiatry, The University of Melbourne, Austin Hospital, Austin Health, Victoria, Australia. email@example.com|
|Citation:||The Australian and New Zealand Journal of Psychiatry; 39(3): 146-53|
|Abstract:||To review serotonergic and dopaminergic system function in anorexia nervosa in terms of potential modulation by atypical antipsychotic medications.A systematic review of clinical, neurobiological and functional neuroimaging findings of serotonergic and dopaminergic system activity in anorexia nervosa was conducted via MEDLINE, PsycINFO and EMBASE psychiatry databases, with a critical review of dysregulation of these systems as therapeutic targets for atypical antipsychotics, in context of evidence regarding the utility and efficacy of these medications in this syndrome.There is evidence of persistently altered serotonergic and dopaminergic function in anorexia nervosa independent to weight-recovery. Case reports, open-label and single-blinded studies, albeit sparse, suggest that atypical antipsychotics may be beneficial in the management of anorexia nervosa psychopathology beyond weight gain.Double-blind placebo controlled studies of atypical antipsychotics in anorexia nervosa with well defined outcome measures are required.|
|Internal ID Number:||15701063|
|Subjects:||Anorexia Nervosa.drug therapy.physiopathology|
Antipsychotic Agents.therapeutic use
Randomized Controlled Trials as Topic
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.